Pharmacotherapy options for managing hepatitis B in children

References

• Ott JJ, Horn J, Krause G, et al. Time trends of chronic HBV infection over prior decades – a global analysis. J Hepatol. 2017;66(1):48–54.
   PubMed Web of Science ®Google Scholar
• Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399–1408.
   PubMed Web of Science ®Google Scholar
• Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016;388(10049):1081–1088.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global health sector strategy on viral hepatitis, 2016–2021. [ cited 2020 Mar 12]. Available from: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1
   Google Scholar
• World Health Organization. Global hepatitis report 2017. [ cited 2020 Mar 26]. Available from: https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf
   Google Scholar
• World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. [ cited 2020 Mar 26]. Available from: https://apps.who.int/iris/bitstream/handle/10665/154590/9789241549059_eng.pdf;jsessionid=8A0AD7930148A7F9FFFADBFF68DCF4BB?sequence=1
   Google Scholar
• Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053–2063.
   PubMed Web of Science ®Google Scholar
• Mysore KR, Leung DH. Hepatitis B and C. Clin Liver Dis. 2018;22(4):703–722.
   PubMed Web of Science ®Google Scholar
• Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035.
   PubMed Web of Science ®Google Scholar
• Seto WK, Lo YR, Pawlotsky JM, et al. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313–2324.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–283.
   PubMed Web of Science ®Google Scholar
• Kennedy PTF, Litwin S, Dolman GE, et al. Immune Tolerant Chronic Hepatitis B: the Unrecognized Risks. Viruses. 2017;9(5). DOI:10.3390/v9050096
   Web of Science ®Google Scholar
• EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–185. DOI:10.1016/j.jhep.2012.02.010
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398.
   PubMed Web of Science ®Google Scholar
• Mason WS, Gill US, Litwin S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology. 2016;151(5):986–998e984.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599.
   PubMed Web of Science ®Google Scholar
• Vegnente A, Guida S, Lobo-Yeo A, et al. T lymphocyte activation is associated with viral replication in chronic hepatitis B virus infection of childhood. Clin Exp Immunol. 1991;84(2):190–194.
   PubMed Web of Science ®Google Scholar
• Zhu S, Zhang H, Dong Y, et al. The correlation between T helper type 17 cells and clinical characters in Chinese paediatric patients with chronic hepatitis B. Clin Exp Immunol. 2013;171(3):307–312.
   PubMed Web of Science ®Google Scholar
• Heiberg IL, Pallett LJ, Winther TN, et al. Defective natural killer cell anti-viral capacity in paediatric HBV infection. Clin Exp Immunol. 2015;179(3):466–476.
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, King WC, Lisker-Melman M, et al. Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. J Viral Hepat. 2019;26(7):856–865.
   PubMed Web of Science ®Google Scholar
• Lok AS, Zoulim F, Dusheiko G, et al. Hepatitis B cure: from discovery to regulatory approval. Hepatology. 2017;66(4):1296–1313.
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001–1010.
   PubMed Web of Science ®Google Scholar
• Jonas MM, Lok AS, McMahon BJ, et al. Antiviral therapy in management of chronic hepatitis B viral infection in children: a systematic review and meta-analysis. Hepatology. 2016;63(1):307–318.
   PubMed Web of Science ®Google Scholar
• Marx G, Martin SR, Chicoine JF, et al. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis. 2002;186(3):295–301.
   PubMed Web of Science ®Google Scholar
• Iorio R, Giannattasio A, Cirillo F, et al. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis. 2007;45(8):943–949.
   PubMed Web of Science ®Google Scholar
• Popalis C, Yeung LT, Ling SC, et al. Chronic hepatitis B virus (HBV) infection in children: 25 years’ experience. J Viral Hepat. 2013;20(4):e20–26.
   PubMed Web of Science ®Google Scholar
• Komatsu H, Inui A, Sogo T, et al. Chronic hepatitis B virus infection in children and adolescents in Japan. J Pediatr Gastroenterol Nutr. 2015;60(1):99–104.
   PubMed Web of Science ®Google Scholar
• Wen WH, Chang MH, Hsu HY, et al. The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J Pediatr. 2004;144(3):397–399.
   PubMed Web of Science ®Google Scholar
• Zacharakis G, Koskinas J, Kotsiou S, et al. Natural history of chronic hepatitis B virus infection in children of different ethnic origins: a cohort study with up to 12 years’ follow-up in northern Greece. J Pediatr Gastroenterol Nutr. 2007;44(1):84–91.
   PubMed Web of Science ®Google Scholar
• Bortolotti F, Jara P, Crivellaro C, et al. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol. 1998;29(2):184–190.
   PubMed Web of Science ®Google Scholar
• Boxall EH, Sira J, Standish RA, et al. Natural history of hepatitis B in perinatally infected carriers. Arch Dis Child Fetal Neonatal Ed. 2004;89(5):F456–460.
   PubMed Web of Science ®Google Scholar
• Manzat Saplacan RM, Mircea PA, Valean SD, et al. The long-term evolution of chronic hepatitis B acquired in childhood. J Gastrointestin Liver Dis. 2009;18(4):433–438.
   PubMed Web of Science ®Google Scholar
• Kew MC, Hodkinson J, Paterson AC, et al. Hepatitis-B virus infection in black children with hepatocellular carcinoma. J Med Virol. 1982;9(3):201–207.
   PubMed Web of Science ®Google Scholar
• Moore SW, Millar AJ, Hadley GP, et al. Hepatocellular carcinoma and liver tumors in South African children: a case for increased prevalence. Cancer. 2004;101(3):642–649.
   PubMed Web of Science ®Google Scholar
• Moore SW, Davidson A, Hadley GP, et al. Malignant liver tumors in South African children: a national audit. World J Surg. 2008;32(7):1389–1395.
   PubMed Web of Science ®Google Scholar
• Hsu HC, Wu MZ, Chang MH, et al. Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis. J Hepatol. 1987;5(3):260–267.
   PubMed Web of Science ®Google Scholar
• Chang MH, Chen DS, Hsu HC, et al. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer. 1989;64(11):2377–2380.
   PubMed Web of Science ®Google Scholar
• Cheah PL, Looi LM, Lin HP, et al. Childhood primary hepatocellular carcinoma and hepatitis B virus infection. Cancer. 1990;65(1):174–176.
   PubMed Web of Science ®Google Scholar
• Tazawa Y, Nishinomiya F, Noguchi H, et al. Hepatocellular carcinoma in children with hepatitis B surface antigen. Tohoku J Exp Med. 1992;167(1):47–55.
   PubMed Web of Science ®Google Scholar
• Akinyinka OO, Falade AG, Ogunbiyi O, et al. Hepatocellular carcinoma in Nigerian children. Ann Trop Paediatr. 2001;21(2):165–168.
   PubMed Web of Science ®Google Scholar
• Zhang XF, Liu XM, Wei T, et al. Clinical characteristics and outcome of hepatocellular carcinoma in children and adolescents. Pediatr Surg Int. 2013;29(8):763–770.
   PubMed Web of Science ®Google Scholar
• Mogul DB, Ling SC, Murray KF, et al. Characteristics of hepatitis B virus-associated hepatocellular carcinoma in children: a multi-center study. J Pediatr Gastroenterol Nutr. 2018;67(4):437–440.
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.
   PubMed Web of Science ®Google Scholar
• Sokal EM, Paganelli M, Wirth S, et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European society of pediatric gastroenterology, hepatology and nutrition. J Hepatol. 2013;59(4):814–829.
   PubMed Web of Science ®Google Scholar
• Jonas MM, Block JM, Haber BA, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology. 2010;52(6):2192–2205.
   PubMedGoogle Scholar
• Schwimmer JB, Dunn W, Norman GJ, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology. 2010;138(4):1357–1364, 1364 e1351–1352.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18–35.
   PubMed Web of Science ®Google Scholar
• Pan XB, Lu YQ, Lin SZ, et al. An assessment of upper limits of normal for ALT and the impact on evaluating natural course of chronic hepatitis B virus infection in chinese children. Am J Gastroenterol. 2018;113(11):1660–1668.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68(2):723–750.
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47.
   PubMed Web of Science ®Google Scholar
• Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138(2):493–502.
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Di Bisceglie AM, Waggoner JG, et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology. 1993;104(4):1116–1121.
   PubMed Web of Science ®Google Scholar
• Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 1995;109(3):908–916.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Ghoshal UC, Naik SR. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries. Natl Med J India. 2002;15(6):320–327.
   PubMed Web of Science ®Google Scholar
• Toy M, Onder FO, Idilman R, et al. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ. 2012;13(5):663–676.
   PubMed Web of Science ®Google Scholar
• Allain JP, Opare-Sem O. Screening and diagnosis of HBV in low-income and middle-income countries. Nat Rev Gastroenterol Hepatol. 2016;13(11):643–653.
   PubMed Web of Science ®Google Scholar
• Spearman CW, Afihene M, Ally R, et al. Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. Lancet Gastroenterol Hepatol. 2017;2(12):900–909.
   PubMed Web of Science ®Google Scholar
• Tan G, Song H, Xu F, et al. When hepatitis B virus meets interferons. Front Microbiol. 2018;9:1611.
   PubMed Web of Science ®Google Scholar
• Mani SKK, Andrisani O. Interferon signaling during hepatitis B virus (HBV) infection and HBV-associated hepatocellular carcinoma. Cytokine. 2019;124:154518.
   PubMed Web of Science ®Google Scholar
• Lai CL, Lok AS, Lin HJ, et al. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet. 1987;2(8564):877–880.
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno M, Rua MJ, Molina J, et al. Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology. 1991;13(6):1035–1039.
   PubMed Web of Science ®Google Scholar
• Utili R, Sagnelli E, Galanti B, et al. Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2a-interferon: a controlled, randomized study. Am J Gastroenterol. 1991;86(3):327–330.
   PubMed Web of Science ®Google Scholar
• Barbera C, Bortolotti F, Crivellaro C, et al. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology. 1994;20(2):287–290.
   PubMed Web of Science ®Google Scholar
• Gregorio GV, Jara P, Hierro L, et al. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology. 1996;23(4):700–707.
   PubMed Web of Science ®Google Scholar
• Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology. 1998;114(5):988–995.
   PubMed Web of Science ®Google Scholar
• Bortolotti F, Jara P, Barbera C, et al. Long term effect of alpha interferon in children with chronic hepatitis B. Gut. 2000;46(5):715–718.
   PubMed Web of Science ®Google Scholar
• Vo Thi Diem H, Bourgois A, Bontems P, et al. Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls. J Pediatr Gastroenterol Nutr. 2005;40(2):141–145.
   PubMed Web of Science ®Google Scholar
• Boxall EH, Sira J, Ballard AL, et al. Long-term follow-up of hepatitis B carrier children treated with interferon and prednisolone. J Med Virol. 2006;78(7):888–895.
   PubMed Web of Science ®Google Scholar
• Hsu HY, Tsai HY, Wu TC, et al. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan. Liver Int. 2008;28(9):1288–1297.
   PubMed Web of Science ®Google Scholar
• Vajro P, Tedesco M, Fontanella A, et al. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection. Pediatr Infect Dis J. 1996;15(3):223–231.
   PubMed Web of Science ®Google Scholar
• El Sherbini A, Omar A. Treatment of children with HBeAg-positive chronic hepatitis B: a systematic review and meta-analysis. Dig Liver Dis. 2014;46(12):1103–1110.
   PubMedGoogle Scholar
• Kobak GE, MacKenzie T, Sokol RJ, et al. Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger. J Pediatr. 2004;145(3):340–345.
   PubMed Web of Science ®Google Scholar
• Wai CT, Chu CJ, Hussain M, et al. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology. 2002;36(6):1425–1430.
   PubMed Web of Science ®Google Scholar
• Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut. 2005;54(7):1009–1013.
   PubMed Web of Science ®Google Scholar
• Perry CM, Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs. 2001;61(15):2263–2288.
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682–2695.
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365(9454):123–129.
   PubMed Web of Science ®Google Scholar
• Wirth S, Zhang H, Hardikar W, et al. Efficacy and safety of peginterferon Alfa-2a (40KD) in children with chronic hepatitis B: the PEG-B-ACTIVE study. Hepatology. 2018;68(5):1681–1694.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li H, Yan X, et al. Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B. J Viral Hepat. 2019;26(Suppl 1):69–76.
   PubMedGoogle Scholar
• Hu Y, Ye YZ, Ye LJ, et al. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China. World J Pediatr. 2019;15(6):595–600.
   PubMed Web of Science ®Google Scholar
• Fan H, Lin L, Jia S, et al. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B. J Viral Hepat. 2019;26(Suppl 1):77–84.
   PubMedGoogle Scholar
• Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology. 2011;140(2):450–458e451.
   PubMed Web of Science ®Google Scholar
• Kasirga E. Lamivudine resistance in children with chronic hepatitis B. World J Hepatol. 2015;7(6):896–902.
   PubMed Web of Science ®Google Scholar
• Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res. 2004;64(1):1–15.
   PubMed Web of Science ®Google Scholar
• Jonas MM, Mizerski J, Badia IB, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002;346(22):1706–1713.
   PubMed Web of Science ®Google Scholar
• Sokal EM, Kelly DA, Mizerski J, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology. 2006;43(2):225–232.
   PubMed Web of Science ®Google Scholar
• Qaqish RB, Mattes KA, Ritchie DJ. Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. Clin Ther. 2003;25(12):3084–3099.
   PubMed Web of Science ®Google Scholar
• Shaw T, Bowden S, Locarnini S. Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy? Gastroenterology. 2004;126(1):343–347.
   PubMed Web of Science ®Google Scholar
• Jonas MM, Kelly D, Pollack H, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology. 2008;47(6):1863–1871.
   PubMed Web of Science ®Google Scholar
• Jonas MM, Kelly D, Pollack H, et al. Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. Pediatr Infect Dis J. 2012;31(6):578–582.
   PubMed Web of Science ®Google Scholar
• Tang LSY, Covert E, Wilson E, et al. Chronic hepatitis B infection: a review. JAMA. 2018;319(17):1802–1813.
   PubMed Web of Science ®Google Scholar
• Chu M, Cho SM, Choe BH, et al. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. J Pediatr Gastroenterol Nutr. 2012;55(6):648–652.
   PubMed Web of Science ®Google Scholar
• Jenh AM, Thio CL, Pham PA. Tenofovir for the treatment of hepatitis B virus. Pharmacotherapy. 2009;29(10):1212–1227.
   PubMed Web of Science ®Google Scholar
• Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595–612.
   PubMed Web of Science ®Google Scholar
• Murray KF, Szenborn L, Wysocki J, et al. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology. 2012;56(6):2018–2026.
   PubMed Web of Science ®Google Scholar
• Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118(3):e711–718.
   PubMed Web of Science ®Google Scholar
• Lim Y, Lyall H, Foster C. Tenofovir-associated nephrotoxicity in children with perinatally-acquired HIV infection: a single-centre cohort study. Clin Drug Investig. 2015;35(5):327–333.
   PubMed Web of Science ®Google Scholar
• Choe JY, Ko JS, Choe BH, et al. Antiviral efficacy of tenofovir monotherapy in children with nucleos(t)ide-naive chronic hepatitis B. J Korean Med Sci. 2018;33(2):e11.
   PubMed Web of Science ®Google Scholar
• van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006;44(2):318–325.
   PubMed Web of Science ®Google Scholar
• Wong SN, Lok AS. Tenofovir disoproxil fumarate: role in hepatitis B treatment. Hepatology. 2006;44(2):309–313.
   PubMed Web of Science ®Google Scholar
• Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139(4):1218–1229.
   PubMed Web of Science ®Google Scholar
• Gao L, Trinh HN, Li J, et al. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther. 2014;39(6):629–637.
   PubMed Web of Science ®Google Scholar
• Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59(2):434–442.
   PubMed Web of Science ®Google Scholar
• Liu Y, Corsa AC, Buti M, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat. 2017;24(1):68–74.
   PubMed Web of Science ®Google Scholar
• Jiang D, Wang J, Zhao X, et al. Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance. Liver Int. 2020;40(1):83–91.
   PubMed Web of Science ®Google Scholar
• Park ES, Lee AR, Kim DH, et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol. 2019;70(6):1093–1102.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Viread. [ cited July 11]. https://www.ema.europa.eu/en/medicines/human/EPAR/viread#product-information-section
   Google Scholar
• Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185–195.
   PubMed Web of Science ®Google Scholar
• Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196–206.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Vemlidy. [ cited 2020 June 2]. https://www.ema.europa.eu/en/medicines/human/EPAR/vemlidy#overview-section
   Google Scholar
• Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011–1020.
   PubMed Web of Science ®Google Scholar
• Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology. 2009;49(1):72–79.
   PubMed Web of Science ®Google Scholar
• Jonas MM, Chang MH, Sokal E, et al. Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B. Hepatology. 2016;63(2):377–387.
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49(5):1503–1514.
   PubMed Web of Science ®Google Scholar
• Chang KC, Wu JF, Hsu HY, et al. Entecavir treatment in children and adolescents with chronic hepatitis B virus infection. Pediatr Neonatol. 2016;57(5):390–395.
   PubMed Web of Science ®Google Scholar
• Lee KJ, Choe BH, Choe JY, et al. A multicenter study of the antiviral efficacy of entecavir monotherapy compared to lamivudine monotherapy in children with nucleos(t)ide-naive chronic hepatitis B. J Korean Med Sci. 2018;33(8):e63.
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005;129(4):1198–1209.
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007;51(3):902–911.
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008;48(1):99–108.
   PubMed Web of Science ®Google Scholar
• Lai CL, Lin HJ, Lau JN, et al. Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med. 1991;78(286):155–163.
   PubMedGoogle Scholar
• D’Antiga L, Aw M, Atkins M, et al. Combined lamivudine/interferon-alpha treatment in “immunotolerant” children perinatally infected with hepatitis B: a pilot study. J Pediatr. 2006;148(2):228–233.
   PubMed Web of Science ®Google Scholar
• Kramvis A, Kostaki EG, Hatzakis A, et al. Immunomodulatory function of HBeAg related to short-sighted evolution, transmissibility, and clinical manifestation of hepatitis B virus. Front Microbiol. 2018;9:2521.
   PubMed Web of Science ®Google Scholar
• Crispe IN. Hepatic T cells and liver tolerance. Nat Rev Immunol. 2003;3(1):51–62.
   PubMed Web of Science ®Google Scholar
• Hong M, Bertoletti A. Tolerance and immunity to pathogens in early life: insights from HBV infection. Semin Immunopathol. 2017;39(6):643–652.
   PubMed Web of Science ®Google Scholar
• Kennedy PTF, Sandalova E, Jo J, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology. 2012;143(3):637–645.
   PubMed Web of Science ®Google Scholar
• Alatrakchi N, Koziel MJ. Antiviral T-cell responses and therapy in chronic hepatitis B. J Hepatol. 2003;39(4):631–634.
   PubMed Web of Science ®Google Scholar
• Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest. 1998;102(5):968–975.
   PubMed Web of Science ®Google Scholar
• Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology. 2001;33(4):963–971.
   PubMed Web of Science ®Google Scholar
• Carey I, D’Antiga L, Bansal S, et al. Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy. J Virol. 2011;85(5):2416–2428.
   PubMed Web of Science ®Google Scholar
• Marrone A, Zampino R, Portella G, et al. Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B.. J Viral Hepat. 2005;12(2):186–191.
   PubMed Web of Science ®Google Scholar
• Poddar U, Yachha SK, Agarwal J, et al. Cure for immune-tolerant hepatitis B in children: is it an achievable target with sequential combo therapy with lamivudine and interferon? J Viral Hepat. 2013;20(5):311–316.
   PubMed Web of Science ®Google Scholar
• Zhu S, Zhang H, Dong Y, et al. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: a pilot open-label randomized study. J Hepatol. 2018;68(6):1123–1128.
   PubMed Web of Science ®Google Scholar
• Rosenthal P, Ling SC, Belle SH, et al. Combination of entecavir/peginterferon Alfa-2a in children with hepatitis b e antigen-positive immune tolerant chronic hepatitis B virus infection. Hepatology. 2019;69(6):2326–2337.
   PubMed Web of Science ®Google Scholar
• Tatsukawa Y, Tsuge M, Kawakami Y, et al. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study. Antivir Ther. 2018;23(8):639–646.
   PubMed Web of Science ®Google Scholar
• Lin CL, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver Int. 2016;36(Suppl 1):85–92.
   PubMed Web of Science ®Google Scholar
• Revill P, Testoni B, Locarnini S, et al. Global strategies are required to cure and eliminate HBV infection. Nat Rev Gastroenterol Hepatol. 2016;13(4):239–248.
   PubMed Web of Science ®Google Scholar
• Asselah T, Loureiro D, Boyer N, et al. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure. Lancet Gastroenterol Hepatol. 2019;4(11):883–892.
   PubMed Web of Science ®Google Scholar
• Revill PA, Chisari FV, Block JM, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545–558.
   PubMed Web of Science ®Google Scholar
• Martinez MG, Villeret F, Testoni B, et al. Can we cure hepatitis B virus with novel direct-acting antivirals? Liver Int. 2020;40(Suppl 1):27–34.
   PubMedGoogle Scholar
• Cornberg M, Lok AS, Terrault NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(‡). J Hepatol. 2020;72(3):539–557.
   PubMed Web of Science ®Google Scholar
• Smolders EJ, Burger DM, Feld JJ, et al. Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. Aliment Pharmacol Ther. 2020;51(2):231–243.
   PubMed Web of Science ®Google Scholar
• Sekiba K, Otsuka M, Ohno M, et al. Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx-DDB1 interaction. Cell Mol Gastroenterol Hepatol. 2019;7(2):297–312.
   PubMed Web of Science ®Google Scholar
• Indolfi G, Abdel-Hady M, Bansal S, et al. Management of hepatitis B virus infection and prevention of hepatitis B virus reactivation in children with acquired immunodeficiencies or undergoing immune suppressive, cytotoxic, or biological modifier therapies. J Pediatr Gastroenterol Nutr. 2020;70(4):527–538.
   PubMed Web of Science ®Google Scholar
• Brown RS Jr., McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology. 2016;63(1):319–333.
   PubMed Web of Science ®Google Scholar
• Song J, Yang F, Wang S, et al. Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: a meta-analysis. J Viral Hepat. 2019;26(3):397–406.
   PubMed Web of Science ®Google Scholar
• Desalegn H, Aberra H, Berhe N, et al. Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia. BMC Med. 2018;16(1):234.
   PubMedGoogle Scholar
• Clemente MG, Antonucci R, Sotgiu G, et al. Present and future management of viral hepatitis B and C in children. Clin Res Hepatol Gastroenterol. 2020 Mar;12:S2210–7401(20)30043–7. Online ahead of print.
   Google Scholar
• Rowland M, McGee A, Broderick A, et al. Repeatability of transient elastography in children. Pediatr Res. 2020. DOI:10.1038/s41390-020-0916-4
   PubMed Web of Science ®Google Scholar
• Goldschmidt I, Streckenbach C, Dingemann C, et al. Application and limitations of transient liver elastography in children. J Pediatr Gastroenterol Nutr. 2013;57(1):109–113.
   PubMed Web of Science ®Google Scholar
• Loomba R, Liu J, Yang HI, et al. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11(12):1636–1645e1631–1633.
   PubMed Web of Science ®Google Scholar
• Seto WK, Yuen MF. Viral hepatitis: ‘Immune tolerance’ in HBV infection: danger lurks. Nat Rev Gastroenterol Hepatol. 2016;13(11):627–628.
   PubMed Web of Science ®Google Scholar
• Zhu S, Dong Y, Wang L, et al. Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B. J Hepatol. 2019;71(5):871–875.
   PubMed Web of Science ®Google Scholar